eGene's DNA Analyzer Used for Anti-Tumor Medication-Related Large-Scale Population Genotyping
News Apr 26, 2006
eGene Inc. has announced that its analyzer was used in large-scale screening for genotyping related to anti-tumor medication and was found to be a highly efficient tool in a clinical laboratory setting.
The research report will be published in the coming issue of Analytical Biochemistry 352 (2006) 148-150.
Dr. Ming S. Liu, acting CEO of eGene, noted, "A recent study has demonstrated that the determination of a certain individual genotype will be essential to future anti-tumor medication."
"The genotype of an enzyme (deoxycytidine Kinase) in our body may represent a significant influence on the efficacy for acute myeloid leukemia treatment."
"The result of genotyping will not only provide information for patient treatment, but also indicate the direction of future cancer drug development."
"The best way for future medication would be to identify the individual genotype of certain genes and treat the disease with the right medicine," he continued.
"Our HDA-GT12 genetic analyzer could play a major role in genotyping analysis. It is a compact, low-cost, automated digital genotyping system, which will be useful in hospitals, outpatient facilities, clinical laboratories and the pharmaceutical industry for medication-related genotyping analysis."
The HDA-GT12™ Genetic Analyzer is in use at 100 hospitals and research centers worldwide. The system analyzes genetic fingerprinting of living organisms through microsatellites, AFLP and RFLP.
It is designed do perform fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp).
The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures quality of fragmented cRNA.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.